Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges

Madhav V. Dhodapkar¹,²

¹Hematology Section, Yale University School of Medicine, New Haven, CT 06510, USA, ²Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10065, USA

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Diversity of CD1d restricted natural killer T cells
4. Tissue distribution and subsets of CD1d restricted T cells in humans and mice
5. Anti-tumor properties of NKT cells in mice
6. Enhancement of tumor growth by type II NKT cells
7. Studies of NKT cells in human cancer
8. Manipulating human NKT cells in vivo
   8.1. Soluble α-GalCer therapy
   8.2. α-GalCer loaded dendritic cells
9. Improving NKT targeting in the clinic
   9.1. Patient Selection
   9.2. Alternate ligands
   9.3. Combination Therapies
   9.4. Harnessing adjuvant properties of NKT cells
10. Challenges for targeting NKT cells in the clinic
    10.1. Humans versus mice
    10.2. Type I versus II NKT cells
    10.3. Role of tissue and tumor microenvironments
11. Summary
12. Acknowledgments
13. References

1. ABSTRACT

Glycolipid reactive CD1d restricted natural killer T (NKT) cells represent a distinct population of T cells implicated in the regulation of immune responses in a broad range of diseases including cancer. Several studies have demonstrated the capacity of NKT cells bearing an invariant T cell receptor (iNKT cells) to recruit both innate and adaptive anti-tumor immunity and mediate tumor rejection in mice. Early phase clinical studies in humans have demonstrated the capacity of dendritic cells (DCs) to mediate expansion of NKT cells in vivo. However several challenges need to be overcome in order to effectively harness the properties of these cells in the clinic.

2. INTRODUCTION

The immune system has several cellular components that can theoretically be recruited for protection from tumors.(1) CD4+ and CD8+ T cells recognize peptide ligands in the context of major histocompatibility complex (MHC) I and II products and are the critical adaptive components of cell-mediated immunity. In contrast, a distinct subset of T cells termed natural killer T (NKT) cells does not respond to peptide antigens but to glycolipid ligands in the context of CD1d molecules on antigen presenting cells.(2) The role of CD4 and CD8+ T cells in anti-tumor immunity is extensively studied.(1) Over the past several years, there have been
Harnessing NKT cells in cancer

**Figure 1.** Balance of immune-regulatory NKT subpopulations. A growing body of data suggests that the balance of two distinct types of CD1d restricted NKT cells may impact the balance of tumor immunity.

<table>
<thead>
<tr>
<th>CD1d restricted T cell receptor</th>
<th>Type I NKT</th>
<th>Type II NKT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor Immunity</td>
<td>Enhance</td>
<td>Suppress</td>
</tr>
<tr>
<td>Targeting Ligand</td>
<td>α-GalCer</td>
<td>Unknown</td>
</tr>
<tr>
<td>Cytokine Profile</td>
<td>IFNγ, IL4</td>
<td>?IL13</td>
</tr>
<tr>
<td>Tumor derived Ligands</td>
<td>Unknown</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

considerable advances in understanding the biology of antigen presentation of glycolipids and the possible role of NKT cells in anti-tumor immunity, particularly in mice.(3) This review focuses on the potential capacity of these glycolipid reactive T cells to modulate tumor immunity. I will particularly emphasize the data from studies with human cells and studies harnessing this aspect of the immune system in the clinic.

**3. DIVERSITY OF CD1D RESTRICTED NATURAL KILLER T CELLS**

NKT cells were first characterized in mice as cells that express both T cell receptor (TCR) and NK1.1, a C-lectin type NK receptor.(4) This definition however does not satisfactorily delineate the spectrum of glycolipid reactive lymphocytes.(2,5) This has led to a revised nomenclature that emphasizes the CD1d restricted nature of these cells.(2,6-8) At least 3 distinct subsets of NKT cells exist, and these distinctions may have major implications for role of NKT cells in regulating tumor immunity.(9) Much of the current data is restricted to T cells staining with CD1d tetramers loaded with a synthetic ligand, α-galactosyl ceramide (α-GalCer). These cells express an invariant T cell receptor (Vα14 in mice and Vα24 in humans), and are termed as type I NKT cells or invariant NKT (iNKT) cells.(10) These cells are also the subject of much of the discussion below, due to their anti-tumor properties (Figure 1). However, it has also become clear that several of the glycolipid reactive CD1d restricted T cells, particularly in humans, lack invariant TCR (termed type II NKT cells).(11-15) Finally, there is a heterogeneous subset of T cells with diverse TCRs that express NK markers, but are not CD1d restricted or glycolipid reactive, and are termed type III NKT cells.(16) These latter cells are diverse in their phenotypic and functional properties and not discussed here.

**4. TISSUE DISTRIBUTION AND SUBSETS OF CD1D RESTRICTED T CELLS IN HUMANS AND MICE**

In mice, the primary site for iNKT cells is the liver, where they account for 20-40% of intrahepatic lymphocytes. In humans, the frequency of iNKT cells is much lower than in mice (including in the human liver), although there is considerable interindividual heterogeneity.(2,8) In contrast, a sizeable population of CD1d restricted T cells in the human bone marrow and liver may consist of type II NKT cells.(12,13) Human iNKT cells include at least 2 major subsets, CD4+ and double negative (CD4-CD8-), although CD8+ NKT cells have also been described.(17,18) Functionally, the different subsets of human iNKT cells differ in terms of their ability to produce cytokines *in vitro* and expression of chemokine receptors. For example, IL-4 production appears to be largely restricted to the CD4+ subset, while the double negative subset can produce interferon-γ. In mice, such differences in cytokine producing capacities of different cytokine subsets are less clear. Differences in tissue distribution or cytokine production of different NKT populations may however have a major impact on the anti-tumor properties of these cells. For example, recent studies in two different mouse models suggest that the capacity of iNKT cells to stimulate anti-tumor immunity after adoptive transfer may depend on their organ of origin.(19) In contrast to liver derived NKT cells, those derived from spleen or thymus were less capable of tumor rejection.(19) Even within liver iNKT cells, CD4- iNKT cells were more potent tumor suppressors than their CD4+ counterparts. These issues may potentially be important for optimal enhancement of tumor immunity *in vivo*, as current approaches rely largely on systemic activation of NKT compartments concurrently in several tissues, which may be counterproductive. Whether the differences in frequency, tissue distribution, subtypes and subsets of CD1d restricted T cells in mice versus humans will have an impact on our ability to translate findings from mouse to human, remains to be determined. However they do emphasize the need to directly study humans to probe the biology of these cells, and urge caution regarding “translating” results between species.

**5. ANTI-TUMOR PROPERTIES OF NKT CELLS IN MICE**

Several studies have demonstrated the potential importance of NKT cells in tumor rejection in mice.(3,8,20,21) Upon challenge with chemical carcinogen methylchloranthrene (MCA), mice deficient in CD1d or iNKT cells are more susceptible to tumor growth, with both an earlier onset of tumor development, as well as higher incidence of tumors.(22) These tumors exhibit an unedited
Harnessing NKT cells in cancer

Evidence for the anti-tumor effects of iNKT cells has also come from the experimental approaches to treat cancer. iNKT cells were found to be necessary for IL-12 mediated anti-tumor immunity in some models (25). The discovery of α-galactosylceramide (α-GalCer) as an iNKT ligand was driven largely based on its anti-tumor properties and the ability to promote NKT and CD1d dependent rejection of a broad range of tumors including melanoma, thymoma, carcinoma, and sarcoma.(26) α-GalCer can also mediate protection against chemical or oncogene dependent tumors in mice (27). The anti-tumor effects of α-GalCer involves a complex interplay of several effectors and molecules and seems to depend on its ability to induce strong production of interferon-γ in vivo.(28, 29) In addition to cytokine production and direct cytolytic function, iNKT activation can also lead to activation of other “downstream” effectors (30-33). For example, iNKT cells can cause rapid activation of NK cells in vivo in mice.(30, 31) CD1 restricted T cells, including iNKT cells can also promote DC maturation (34), and DC-NKT cross talk may allow NKT activation during microbial infections in the absence of direct recognition of microbial antigens.(35) α-GalCer mediated activation of iNKT cells may also enhance anti-tumor immunity in vivo in mice by promoting the activation of antigen presenting dendritic cells (DCs) and IL-12 production via CD40 ligand (CD40L) mediated interactions.(36-38) These adjuvant properties of iNKT cells in mice have been reviewed recently (39), and are a particularly exciting area of investigation as they suggest the possibility of harnessing the DC-NKT axis to recruit both innate and adaptive immunity. In addition to the effects on tumor and immune cells, interferon-γ mediated effects of NKT cells likely also involve inhibition of angiogenesis.(40) Consistent with the prime role for interferon-γ production by NKT cells, a C-glycoside analogue of α-GalCer that was more effective at inducing interferon production was also more effective at mediating tumor rejection as well.(41, 42) In addition to T cells, iNKT cells can also activate B cells to increase Ig secretion and therefore provide help for the generation of antibody responses.(43)

6. ENHANCEMENT OF TUMOR GROWTH BY TYPE II NKT CELLS IN MICE

Although the data discussed above support a suppressive effect of NKT cells on tumor growth, NKT cells were also shown to paradoxically enhance tumor growth in some models (44, 45). For example, experimental 15-12RM fibrosarcoma and 4T1 mammary tumors were rejected in CD1d -/- mice, but grew progressively in wild type mice. Tumor enhancement in the 15-12RM model was IL-13 dependent / IL-4 independent, and appeared to involve TGF-β production by a Gr-1+ myeloid cells, that was associated with impaired CTL responses.(46) In contrast, the effects in 4T1 model were IL-13 independent, suggesting that other mechanisms of tumor enhancement exist. CD1d dependent T cells have also been implicated in UV induced inhibition of skin carcinogenesis.(47) More recent studies have shown that the subset of NKT cells (type II) that mediates suppression of tumor immunity in at least some of these studies is different from type I or iNKT cells that suppress tumor growth. Overall, these studies suggest a cross regulation between type I and II NKT cells in regulating tumor immunity.(9, 48) As discussed earlier, the proportion of type II NKT cells may be higher in humans than in mice, although these cells have not yet been studied in the context of human tumors. It is likely that improved understanding of the cross talk between these cells may be needed to effectively translate findings made in mice to humans. Nonetheless, these studies suggest a new immune regulatory axis, between type I and II NKT cells, to regulate tumor immunity. A goal of NKT directed cancer therapies perhaps should be to boost the function of type I NKT cells (such as with α-GalCer or related ligands) relative to type II NKT cells.

7. STUDIES ON NKT CELLS IN HUMAN CANCER

The recognition that iNKT cells can mediate tumor rejection and immune surveillance in vivo and modulate the function of other downstream immune cells has led several investigators to characterize the nature of NKT cells in cancer patients.(49) Most of the effort to date has focused on iNKT cells, due to the lack of tools to monitor reliably human type II NKT cells. Several studies have now reported a deficiency in iNKT numbers and / or function in the blood of patients with advanced cancers.(50, 51) In some settings such as patients with myelodysplastic syndromes, the deficiency is particularly severe, and may relate to developmental defects in the malignant clone.(52, 53) One notable exception are patients with glioma (a tumor lacking systemic metastases) who have normal numbers of circulating iNKT cells.(54) Most of the functional data suggests a deficiency of interferon-producing function of these cells.(50, 51) In many instances such as in multiple myeloma and prostate cancer, this appears to correlate with the clinical stage of tumors, in that the loss of NKT function is observed in patients with more progressive myeloma or hormone refractory advanced prostate cancer.(50, 51) Low levels of circulating iNKT cells were found to predict outcome in patients with head and neck cancer.(55) Nonetheless, these defects can be restored ex vivo after stimulation with α-GalCer bearing APCs suggesting that the observed defects are at least in part, reversible. Expanded NKT cells can then secrete interferon-γ, and even recognize and kill autologous tumors, if appropriately expanded in vitro using α-GalCer.
Harnessing NKT cells in cancer

Table 1. Some approaches to targeting NKT cells in vivo in humans

<table>
<thead>
<tr>
<th>In Clinical Trials</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Soluble ligand (e.g. α-GalCer)</td>
</tr>
<tr>
<td>• Alpha-GalCer loaded DCs</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Under Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Alternate ligands (e.g. α-GalCer analogues)</td>
</tr>
<tr>
<td>• Combination therapies</td>
</tr>
<tr>
<td>- Lenalidomide</td>
</tr>
<tr>
<td>- Cytokines (e.g. IL21, IL15)</td>
</tr>
<tr>
<td>- Monoclonal Antibodies (e.g. anti-DR5, anti-4-1BB)</td>
</tr>
<tr>
<td>• Harnessing adjuvant properties</td>
</tr>
<tr>
<td>- Combination with T cell based vaccines</td>
</tr>
<tr>
<td>- α-GalCer loaded tumor cells</td>
</tr>
</tbody>
</table>

Tumor cells in several hematologic malignancies including leukemia, lymphoma and myeloma have been shown to express CD1d, are NKT sensitive, and therefore particularly interesting targets of iNKT directed therapies.(51, 56-58)

One major caveat of most of the existing data on human NKT cells in cancer is that nearly all the data is based on NKT cells in the blood, and very few studies have analyzed iNKT cells in the tumor tissue itself.(51, 59) This is a critical issue because several aspects of NKT biology such as survival, homing and function may be altered in the tumor bed. The presence of iNKT cells infiltrating primary neuroblastoma tumors was associated with a 2 fold increase in progression free survival.(59) Another study demonstrated that NKT infiltration in primary colorectal tumors was an independent prognostic factor for survival.(60) Even less is known of the mechanisms that regulate function and survival of tumor infiltrating NKT cells. Human iNKT cells were shown to preferentially infiltrate neuroblastomas expressing the chemokine CCL2, suggesting that chemokines / other molecules secreted by tumors may recruit or modify the presence and function of iNKT cells in the tumor bed (59). Overexpression of NMYC by these tumors may repress CCL2 and provide a tumor escape mechanism by preventing NKT localization or survival.(61) Therefore activation of specific oncogenic pathways may directly help tumors escape NKT mediated surveillance. In the case of myeloma, the loss of NKT cell function in the tumor bed correlates with the presence of clinically progressive disease.(51) The mechanism behind the observed loss of NKT effector function in cancer patients is not known. One possibility is that suppressive factors in the tumor bed or ligands expressed by tumor cells may contribute to NKT dysfunction in cancer.(62) Improved understanding of the regulation of NKT function in the tumor bed is needed to better exploit iNKT cells for therapy of cancer.

8. MANIPULATING HUMAN NKT CELLS IN VIVO

NKT cells have been implicated in regulation of a dazzling array of immune responses ranging from immunity to tumors and pathogens to autoimmunity, allergy and transplantation.(2) Therefore the ability to reliably manipulate iNKT cells in vivo in humans has broad therapeutic potential across several medical challenges, and is being actively pursued by several groups (Table 1). α-galactosylceramide (α-GalCer) is a synthetic glycolipid isolated during a screen for anti-cancer agents derived from the marine sponge Agelas mauritius.(63-65) The discovery of α-GalCer as a potent iNKT ligand and its availability as a clinical grade reagent has permitted clinical studies to use this ligand to manipulate NKT cells in humans.(26, 66, 67) To date, all of the attempts to manipulate NKT cells in vivo in humans are based on this single ligand. However it is likely that alternate ligands will also be in the clinic in the near future.

8.1. Soluble alpha-GalCer therapy

As discussed above, injection of α-GalCer in vivo in mice leads to rapid iNKT activation and a “cytokine storm”, which can lead to tumor rejection in some models. In preclinical models, activation of hepatic iNKT cells was thought to carry a potential of hepatotoxicity.(68) Giaconne et al carried out a phase I trial of α-GalCer in patients with advanced cancer.(69) Overall, the infusions were very well tolerated and there was no dose limiting toxicity, including no evidence for hepatotoxicity. However the biologic effects of the infusions were also sobering and associated with only modest and transient changes in some serum cytokines, and transient NKT activation.(69) The individual responses were quite variable and seemed to depend on the baseline frequency of iNKT cells. Tolerability of this therapy has also been tested in a cohort of healthy donors. Based on the data presented at the 3rd NKT/CD1 workshop (but not yet published in a peer reviewed publication), the infusions were again well tolerated, but with only modest effects in terms of NKT activation. A major limitation of soluble α-GalCer therapy may be the induction of long term anergy by this ligand in mice.(52, 70, 71) This has not yet been convincingly documented in the context of human clinical trials of soluble α-GalCer therapy. Nonetheless, these considerations have led to alternate approaches including targeting antigen presenting cells to enhance the activation of NKT cells.

8.2. Alpha-GalCer loaded dendritic cells (DCs)

DCs are professional antigen presenting cells specialized to initiate and regulate immunity.(72, 73) The capacity to generate clinical grade DCs from precursors ex vivo has allowed clinical studies of adoptive transfer of ex vivo generated DCs (73) Prior studies have shown that human and murine DCs are efficient APCs for the stimulation of human iNKT cells in culture and in vivo in mice (74-76). An important difference with reference to targeting antigen to DCs may relate to the induction of anergy.(70, 77) After injection of soluble glycolipid in mice, NKT cells could not be restimulated for at least a month. In contrast, injection of glycolipid loaded DCs led to prolonged NKT activation, without such induction of anergy.(76) Therefore the biologic effect of systemic injection of glycolipid is quite different from the injection of DCs loaded with the same ligand. These data suggest that the nature of antigen presenting cell (APC) presenting the glycolipid to iNKT cells has a major impact on the
Harnessing NKT cells in cancer

The studies discussed above illustrate the feasibility and apparent tolerability of approaches to enhance NKT cells in the setting of human cancer. However the next major challenge is to translate these data into clinically meaningful applications. Below, we discuss some of the approaches being considered.

9. IMPROVING NKT TARGETING IN THE CLINIC

The studies discussed above illustrate the feasibility and apparent tolerability of approaches to enhance NKT cells in the setting of human cancer. However the next major challenge is to translate these data into clinically meaningful applications. Below, we discuss some of the approaches being considered.

9.1. Patient selection

All of the initial studies discussed above were designed to evaluate safety and feasibility of targeting NKT cells in humans and involved patients with highly advanced cancer, including those with prior extensive chemotherapy. These patients by definition had multiple cancer and chemotherapy associated defects in immune system. In my view, it is critical that the next “efficacy studies” be performed in well defined patient populations, preferably with limited prior chemotherapy, in order to systematically ascertain the anti-tumor effects of enhancement of iNKT cells in humans. Although not a prerequisite, it may also be desirable to focus on CD1d expressing tumors (84), such as those with hematologic malignancies. The degree of iNKT dysfunction or deficiency at baseline, as well as the nature of tumor derived CD1d ligands may also be important considerations. For example the cross talk between type I and II NKT cells may determine the outcome of targeting type I NKT cells via α-GalCer or similar ligands.(9)

9.2. Alternate ligands

Recent structural insights into CD1d molecules, their lipid binding pockets, as well as into both canonical and non-canonical T cell receptors (TCR) have provided the framework into rational design of alternate ligands to modify the structure of α-GalCer to increase iNKT activation.(85) Recent studies have also begun to identify the biochemical properties of ligands recognized by both type I (and in the case of sulfatide, type II) NKT cells (86-89). In order to modify the functional properties of α-GalCer, all three components of the molecule (sugar residue, acyl and sphingosine chain) have been targeted.(90) Modifications in the length of the acyl or sphingosine chain can lead to altered stability of the CD1d-lipid complex and altered avidity of binding to TCR.(91) Recent data suggest that analogues with truncation of the sphingosine or the acyl chains can lead to skewing of NKT response towards a Th2 phenotype in mice.(91-93) Interestingly, some of these analogues are still able to lead to activation of dendritic cells.(94) However it is possible that the nature of DC activation and the subsequent effects on adaptive immunity may differ between these analogues and these issues need to be tested in the context of clinical studies. The analogues that induce Th2 responses may be of particular interest in the context of autoimmunity (such as type I diabetes), and may drive the induction of tolerogenic dendritic cells.(95, 96) In contrast, analogues of α-GalCer that seem to lead to greater anti-tumor effects are also being identified.(42, 97)

9.3. Combination therapies

As discussed earlier, it is possible that simply activation of iNKT cells in vivo, even with DCs, may not be sufficient to mediate clinically meaningful anti-tumor effects. This has led to possible combination approaches to enhance the anti-tumor effects of iNKT activation. For example, in the studies by Chang et al, iNKT cells expanded by DCs in vivo still had reduced capacity for secretion of interferon-γ .(81) In subsequent studies, we have observed that lenalidomide, a thalidomide analogue, can enhance costimulation of human iNKT cells, and leads to enhanced secretion of IFN in culture.(98) An advantage of lenalidomide is that it is orally bioavailable and well tolerated as a single agent and therefore can easily be combined with NKT targeted approaches. We hope to
Harnessing NKT cells in cancer

test this combination in the clinic in the near future. Another possible approach is to combine NKT targeted therapy with cytokines such as IL21 and IL15 (99, 100) NKT based approaches combined with anti-DR5 and anti-4-1BB mAb were also effective in eradicating murine tumors, even with previously established tumor models,(101) However the safety of these cytokines or mAbs as single agents first needs to be tested in the clinic. Cytokine dependent recruitment of NKT cells may also enhance graft versus leukemia effects and suppress graft versus host disease in the setting of allogeneic stem cell transplantation (102). These findings are consistent with the report that transplant patients with lower numbers of circulating iNKT cells have more severe GVHD.(103, 104) Another promising approach that is beginning to be tested in the clinic is adoptive transfer of iNKT cells.(105) The feasibility of such approaches has now been demonstrated and it is likely that this will also be combined with in vivo activation of transferred NKT cells.

9.4 Harnessing adjuvant properties of iNKT cells

Although much of the early work focused on the innate functions of NKT cells, more recent studies have emphasized the impact of iNKT cells on the generation of antigen specific T cell responses. The adjuvant properties of glycolipid antigens were first demonstrated in the context of enhanced immunity to a mouse malaria sporozoite vaccine. (33) α-GalCer mediated activation of iNKT cells leads to maturation of dendritic cells (DCs) in vivo, which is associated with enhanced immunostimulatory function.(82, 83) In preclinical studies, tumor immunity induced by the administration of α-GalCer with irradiated tumor cells was superior to other adjuvants such as anti-CD40 antibody or Toll receptor ligands (poly IC or LPS) (106). NKT associated adjuvant effects have also been demonstrated in the context of prime-boost vaccinations and a clinically relevant tumor antigen, NY-ESO1.(94) InNKT mediated DC activation may be synergistic with other adjuvants such as Toll receptor ligands.(94, 107, 108) The adjuvant effects of glycolipids can also be observed in the context of oral or intranasal administration, which are attractive from the perspective of clinical translation.(109, 110) In one study, murine DCs loaded concurrently with peptide and α-GalCer led to greater expansion of antigen specific T cells than DCs loaded with peptide alone. (111) Another interesting approach is loading tumor cells with α-GalCer.(112, 113) Injection of mice with α-GalCer loaded tumors was shown to mediate tumor immunity in an iNKT dependent fashion. Rejection of tumor cells by innate effectors can also lead to cross presentation of dying cells and the generation of long lived tumor immunity.(114) Together, these studies have set the stage for co-administration of glycolipid antigens with T cell based vaccines in order to enhance the induction of tumor specific adaptive immunity.

10. CHALLENGES FOR TARGETING NKT CELLS IN THE CLINIC

Although the pre-clinical and early clinical studies provide rationale and hope for targeting iNKT cells in humans, there remain several challenges before these cells can be safely and effectively targeted in the clinic. Below, I will briefly discuss some of these challenges.

10.1. Humans versus mice

Much of the impressive and elegant work on anti-tumor properties of iNKT cells comes from studies in mice. However the frequencies of iNKT cells in humans are much lower than in mice.(2) As discussed above, there may also be other differences in subsets and functional properties of these cells between species.(115) Both number and function of iNKT cells in cancer patients is further reduced.(51) Therefore the biologic effects of glycolipid ligands may be quite different, at least quantitatively between mice and humans. Although it is possible to reliably increase the number of iNKT cells in humans in vivo (e.g. by DC vaccination or adoptive transfer), there is a paucity of clinical studies specifically targeting human iNKT cells in vivo.

10.2. Type I versus II NKT cells

Recent studies have highlighted the functional diversity of CD1d restricted T cell repertoire.(6) One of the central challenges is the need to better understand the rules by which CD1d restricted T cells can boost or suppress immunity in vivo.(7) This Janus like property of NKT cells, if properly harnessed, could be very useful for a broad range of human diseases, from autoimmunity to tumors, but needs to be better understood. In contrast to mice, a significant proportion of CD1d restricted T cells in humans lack invariant T cell receptor.(2) Recent studies have shown that cross talk with these type II NKT cells can impair tumor protection mediated by iNKT cells.(48, 116) At present, very little is known about the properties of type II NKT cells in human cancer. Here again, there is a need for studies with humans to characterize the nature of ligands recognized by both type I and II NKT cells in vivo in the context of human cancer and their functional properties. Harnessing NKT cells in human cancer may require both enhancing type I and suppressing type II NKT cells.

10.3. Role of tissue and tumor microenvironments

In vivo biology of different NKT subsets and the instructive role of different tissue microenvironments on iNKT function is also poorly understood. In the setting of the tumor bed, cell derived glycolipid ligands (62, 117, 118) may in addition, have a modulating effect on the function of iNKT cells. Functional properties of NKT cells in different tissues may differ. Therefore in contrast to current approaches that lead to systemic NKT activation in multiple tissues, strategies that lead to selective NKT activation in defined tissues may be desirable. Tumor microenvironment may be less permissive to iNKT cells, and strategies to enhance homing and survival of activated iNKT cells to tumor tissues may be needed.

11. SUMMARY

With advances in the biology of antigen presentation of lipids, it is now becoming feasible to learn to harness glycolipid reactive CD1d restricted T cells. A
Harnessing NKT cells in cancer

subset of these cells, termed iNKT cells carry considerable potential for their anti-tumor properties. These cells may also provide critical link between innate and adaptive immunity via activation of DCs. However there is a need for studies in humans to both better understand the biology of these cells and to evaluate the clinical and biologic effects of manipulation of these responses.

12. ACKNOWLEDGMENTS

MVD is supported in part by funds from the National Institutes of Health (NIH; CA106802, CA109465), Damon Runyon Cancer Research Fund, Dana Foundation, and Irma T Hirschl Foundation. This manuscript is dedicated to all of our patients and volunteers who have participated in our studies and clinical trials. The author thanks past and current members of Dhodapkar lab for their contributions.

13. REFERENCES


Harnessing NKT cells in cancer


Harnessing NKT cells in cancer


Harnessing NKT cells in cancer


Harnessing NKT cells in cancer


Harnessing NKT cells in cancer


Abbreviations: α-GalCer: α-galactosylceramide; DC: dendritic cells; NKT: natural killer T cells; iNKT: invariant NKT cells; TCR: T cell receptor; IFN\gamma: interferon-gamma; IL: interleukin; MCA: Methylchloranthrene

Key Words: Innate Immunity, Natural Killer T cells, Glycolipid, Dendritic Cells, Review

Send correspondence to: Madhav V. Dhodapkar, Section of Hematology, Yale University, 333 Cedar Street, Box 208021, New Haven, CT 06510, Tel: 203-785-4144, Fax: 203-785-7232, E-mail: madhav.dhodapkar@yale.edu